SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy
Authors:
Open Access
- 16 April 2022
- journal article
- research article
- Published by International Institute of Anticancer Research in Cancer Genomics & Proteomics
- Vol. 19 (3) , 328-338
Abstract
Background/Aim: Schlafen 12 (SLFN12) expression correlates with survival in triple negative breast cancer (TNBC). SLFN12 slows TNBC proliferation and induces TNBC differentiation, but whether SLFN12 affects the tumoral response to chemotherapy or radiation is unknown. Materials and Methods: We over-expressed SLFN12 in MDA-MB-231 cells using two different lentiviral vectors. We assessed viable cell numbers via crystal violet assay after treatment with carboplatin, paclitaxel, olaparib, zoledronic acid, camptothecin, or cesium irradiation. CHK1 and CHK2 phosphorylation was assessed by western blot and the effects of inhibiting CHK1/CHK2 by AZD7762 were examined. Key findings were confirmed in Hs578t and BT549 TNBC cells after adenoviral SLFN12 over-expression. Results: SLFN12 over-expression increased TNBC sensitivity to radiation, carboplatin, paclitaxel, zoledronic acid, and camptothecin, but not to olaparib. SLFN12 over-expression decreased CHK1 and CHK2 phosphorylation after treatment with the DNA damaging agent camptothecin (CPT). The CHK1/CHK2 inhibitor diminished the significant cytotoxicity difference between over-expression and baseline SLFN12 levels in response to carboplatin. Conclusion: SLFN12 increases TNBC sensitivity to DNA-damaging agents at least in part by reducing CHK1/2 phosphorylation. This may contribute to improved survival in patients whose TNBC over-expresses SLFN12. Therefore, SLFN12 levels may be used to customize or predict radiotherapy and chemotherapy effects in TNBC.Keywords
This publication has 34 references indexed in Scilit:
- Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Breast Cancer Research, 2012
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsProceedings of the National Academy of Sciences, 2012
- Triple-Negative Breast Cancer: An Unmet Medical NeedThe Oncologist, 2011
- Anti-tumour activity of bisphosphonates in preclinical models of breast cancerBreast Cancer Research, 2010
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- BRCA1 and its toolbox for the maintenance of genome integrityNature Reviews Molecular Cell Biology, 2009
- Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break RepairClinical Cancer Research, 2009
- Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage responseDNA Repair, 2009
- Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA BreakageMolecular and Cellular Biology, 2005
- Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitoticsInternational Journal of Cancer, 2005